Literature DB >> 11200779

Effect of melatonin and linolenic acid on mammary cancer in transgenic mice with c-neu breast cancer oncogene.

G N Rao1, E Ney, R A Herbert.   

Abstract

Breast cancer is one of the most common cancers and is a leading cause of mortality in women. The TG.NK transgenic mouse line expresses the c-neu breast cancer oncogene under the control of a MMTV promoter and appears to be a useful animal model for evaluation of intervention strategies to delay/prevent breast cancer. Fiber-rich nonpurified diet (NTP-2000) and some retinoid analogues have been shown to significantly delay the development of mammary cancer in the TG.NK model. Four-week-old hemizygous TG.NK female mice with MMTV/c-neu oncogene fed NTP-2000 diet were gavaged with 0.05-0.2 ml of flaxseed oil as the source of omega-3 rich PUFA, or melatonin at 50-200 mg/kg or a combination of 0.10 ml flaxseed oil and 50 mg/kg melatonin in a gavage volume of 0.2 ml per mouse with corn oil as the vehicle for 30 weeks. The time course of the mammary tumor incidence pattern was advanced by flaxseed oil compared to the control. At the high dose (0.2 ml) of flaxseed oil, when the omega-6: omega-3 PUFA ratio was closer to 1, there was some delay in the growth of mammary tumors. Melatonin delayed the appearance of palpable tumors and the growth of the tumors with a dose-related statistically significant negative trend for the incidence of tumors. The combination of flaxseed oil and melatonin caused a significant decrease in the number of tumors and tumor weight per mouse compared to the control and to flaxseed oil but not to melatonin alone. Flaxseed oil may delay the growth of mammary tumors if the omega-6:omega-3 PUFA ratio of fat consumed is closer to 1. Melatonin has the potential to markedly delay the appearance of palpable mammary tumors. Studies are in progress with the TG.NK mouse model to understand the histological and molecular changes associated with the dose-response pattern of mammary tumor incidence and growth after treatment with a broad range of doses of melatonin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11200779     DOI: 10.1023/a:1026552405042

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression.

Authors:  Thaiz Ferraz Borin; Ali Syed Arbab; Gabriela Bottaro Gelaleti; Lívia Carvalho Ferreira; Marina Gobbe Moschetta; Bruna Victorasso Jardim-Perassi; A S M Iskander; Nadimpalli Ravi S Varma; Adarsh Shankar; Verena Benedick Coimbra; Vanessa Alves Fabri; Juliana Garcia de Oliveira; Debora Aparecida Pires de Campos Zuccari
Journal:  J Pineal Res       Date:  2015-10-20       Impact factor: 13.007

2.  Melatonin, an endogenous hormone, modulates Th17 cells via the reactive-oxygen species/TXNIP/HIF-1α axis to alleviate autoimmune uveitis.

Authors:  Jun Huang; Zhuang Li; Yunwei Hu; Zuoyi Li; Yanyan Xie; Haixiang Huang; Qian Chen; Guanyu Chen; Wenjie Zhu; Yuxi Chen; Wenru Su; Xiaoqing Chen; Dan Liang
Journal:  J Neuroinflammation       Date:  2022-05-27       Impact factor: 9.587

Review 3.  The Pathophysiologic Role of Disrupted Circadian and Neuroendocrine Rhythms in Breast Carcinogenesis.

Authors:  Lonnele J Ball; Oxana Palesh; Lance J Kriegsfeld
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

4.  Nongenotoxic effects and a reduction of the DXR-induced genotoxic effects of Helianthus annuus Linné (sunflower) seeds revealed by micronucleus assays in mouse bone marrow.

Authors:  Marcelo Fabiano Gomes Boriollo; Luiz Silva Souza; Marielly Reis Resende; Thaísla Andrielle da Silva; Nelma de Mello Silva Oliveira; Maria Cristina Costa Resck; Carlos Tadeu dos Santos Dias; João Evangelista Fiorini
Journal:  BMC Complement Altern Med       Date:  2014-04-02       Impact factor: 3.659

5.  Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer.

Authors:  Bruna Victorasso Jardim-Perassi; Ali S Arbab; Lívia Carvalho Ferreira; Thaiz Ferraz Borin; Nadimpalli R S Varma; A S M Iskander; Adarsh Shankar; Meser M Ali; Debora Aparecida Pires de Campos Zuccari
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

Review 6.  Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs.

Authors:  Yoshihiro Hayakawa; Manabu Kawada; Hiroyoshi Nishikawa; Takahiro Ochiya; Hideyuki Saya; Hiroyuki Seimiya; Ryoji Yao; Masahiro Hayashi; Chieko Kai; Akira Matsuda; Tomoki Naoe; Atsushi Ohtsu; Taku Okazaki; Hideo Saji; Masataka Sata; Haruhiko Sugimura; Yuichi Sugiyama; Masakazu Toi; Tatsuro Irimura
Journal:  Cancer Sci       Date:  2016-02       Impact factor: 6.716

Review 7.  Melatonin and urological cancers: a new therapeutic approach.

Authors:  Mohammad Hossein Mehrzadi; Azam Hosseinzadeh; Kobra Bahrampour Juybari; Saeed Mehrzadi
Journal:  Cancer Cell Int       Date:  2020-09-10       Impact factor: 5.722

8.  Effects of miR-34b/miR-892a Upregulation and Inhibition of ABCB1/ABCB4 on Melatonin-Induced Apoptosis in VCR-Resistant Oral Cancer Cells.

Authors:  Ming-Ju Hsieh; Chiao-Wen Lin; Shih-Chi Su; Russel J Reiter; Andy Wei-Ge Chen; Mu-Kuan Chen; Shun-Fa Yang
Journal:  Mol Ther Nucleic Acids       Date:  2020-01-09       Impact factor: 8.886

Review 9.  Efficacy and safety of supplemental melatonin for delayed sleep-wake phase disorder in children: an overview.

Authors:  David Mantle; Marcel Smits; Myrthe Boss; Irene Miedema; Inge van Geijlswijk
Journal:  Sleep Med X       Date:  2020-08-19

10.  Roles of some antioxidants in modulation of cardiac myopathy induced by sodium nitrite via down-regulation of mRNA expression of NF-κB, Bax, and flt-1 and suppressing DNA damage.

Authors:  Laila Mohamed Fadda; Hala A Attia; Nouf Mohamed Al-Rasheed; Hanaa Mahmoud Ali; Nawal Mohamed Al-Rasheed
Journal:  Saudi Pharm J       Date:  2017-12-11       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.